April 19, 2024
Market Now
Celltrion signs W56.8b contract with affiliate
[DISCLOSURE] Celltrion (068270) announced on March 27 that it has signed a sales contract worth 56.8 billion won (US$51.06 million) for its biosimilar Remsima with its affiliate Celltrion Healthcare.
This amounts to 9.41 percent of its 2015 revenue and the contract is valid until March 31.
By Hwang You-mee (theinvestor@heraldcorp.com)
This amounts to 9.41 percent of its 2015 revenue and the contract is valid until March 31.
By Hwang You-mee (theinvestor@heraldcorp.com)
